JPMorgan Chase & Co. (JPM) EPS Comes In At $1.46, Above Estimates

The financial and trading power house JPMorgan Chase & Co. (NYSE:JPM) has reported its results for its Second-Quarter 2014 The highlights of the earnings call was that the New York-headquartered company reported revenue of $25.3 billion for the quarter, and managed to post net income of $6 billion for the reporting period. This was well below the $25.3 billion revenue and $6.5 billion net income reported by the financial institution in the same quarter, last year. Earnings per share for the 2Q operations came in at $1.46. In contrast 2Q13 EPS was at $1.6.

Analysts Prefer JPMorgan Chase & Co. (JPM) Over Citigroup Inc (C)

These strong numbers were reported by JPMorgan Chase & Co. (NYSE:JPM) in spite of the heavy headwinds faced by the financial markets in general and the mortgage vertical in particular during the previous quarter. The other highlights from the earnings call include the healthy $3 billion returns that JPMorgan Chase & Co. (NYSE:JPM) has managed to plough back to its share holders in the form of dividend payout in the reporting quarter in addition to increasing share holder value by repurchasing $1.5 billion in the reporting quarter. The other numbers which stood out in the 2Q14 operations report, was the nearly $93 billion that has been farmed out to consumers as credit by the financial major.

It is interesting to note that, the earnings report by JPMorgan Chase & Co. (NYSE:JPM) was slightly above the earnings expectations of the street. Eric Wasserstrom of SunTrust Robinson Humphrey, on CNBC, anticipated that, “in terms of estimates, from the consensus, I think the consensus is up around $1.30 (for JPMorgan Chase & Co. (NYSE:JPM).” He then went on to underline that investors would be closely watching the “trading line, equity and fixed income” in addition to “advisory results, the underwriting results and, of course, how they control expenses,” when JPMorgan Chase & Co. (NYSE:JPM) comes out with its numbers.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!